.png?width=700&name=New-ATE-Logo2019%20(1).png)
Quantification of Six HCP Lipases from CHO-
Derived Biotherapeutics Using Parallel Reaction
Monitoring and Stable-Isotope Labeled Peptides
Presenter:
Jared Isaac, PhD
Director, Chromatography and Mass Spectrometry,
Director, Chromatography and Mass Spectrometry,
Cygnus Technologies
Jared Isaac, PhD earned his doctoral degree in biomedical research from the University of Cincinnati and his master's degree from Western Michigan University. He has over eight years of industry experience in oncology, molecular diagnostics, medical devices, and biopharmaceutical markets. Trained in both NGS genomics and LC-MS proteomics at Thermo Fisher Scientific, he is an expert in qualitative and quantitative mass spectrometry methods for biopharmaceutical process impurities.
Isaac currently leads Cygnus Technologies’ chromatography and mass spectrometry services for identification and quantification of host cell proteins. He also utilizes antibody affinity extraction (AAE™) in combination with FPLC, UHPLC, 2D-PAGE, and mass spectrometry to enable biopharmaceutical companies to determine whether Cygnus Technologies’ HCP ELISA antibodies have sufficient coverage for the HCPs in their downstream purification process and assess HCP profile in final drug substances.
